News and Trends 6 Feb 2018 Spring Cleaning: AstraZeneca Ditches Underperforming Asthma and Cancer Candidates AstraZeneca has given up on the development of its PD-1 checkpoint inhibitor drug, which was the headline act when its subsidiary MedImmune acquired Amplimmune in 2013. There was no sentiment as pharma giant AstraZeneca cut a number of drugs from its pipeline after they did not perform as expected during clinical trials. The biggest name to get […] February 6, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 6 Feb 2018 New Artificial Intelligence Test for Leukemia Now Available in Europe Sophia Genetics has received a CE-IVD mark for its molecular diagnostics test, which will improve the detection of leukemia. Swiss company Sophia Genetics is a leader in the field of data-driven medicine, with its artificial intelligence (AI) technology already been used to analyze the next-generation sequencing data of over 160,000 patients’ around the world. Today, the company […] February 6, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 6 Feb 2018 Say Hello to a New Biotech Striving to Prevent Kidney Damage During Surgery Balmes Transplantation has raised €700,000 in seed funding to run a proof-of-concept study to test its drug combination for kidney damage. Balmes Transplantation is a young biotech in Marseille, France, that develops combination therapies for a common complication associated with kidney transplants and heart surgery. The biotech has raised a €700,000 seed funding from top company executives and angel […] February 6, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 5 Feb 2018 New Antiviral for RSV Lung Infections Shows Promise in Phase IIa ReViral’s candidate RV521 showed its potential for the treatment of respiratory syncytial virus (RSV) infections by reducing viral load and mucus levels. London-based biotech ReViral discovers and develops antiviral drugs, focusing particularly on the treatment of diseases caused by the respiratory syncytial virus (RSV). The biotech’s candidate, RV521, has undergone a Phase IIa clinical trial during […] February 5, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 3 Feb 2018 Deconstructing Patterns: First Science and Art Exhibition Opens at the Francis Crick Institute Deconstructing patterns, the first exhibition of its kind at the Francis Crick Institute, is the result of months of collaborations between scientists and artists. I got a chance to see it at the opening earlier this week. The new exhibition at the Francis Crick Institute puts into perspective the groundbreaking research happening in the scientists’ […] February 3, 2018 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Feb 2018 The Success Rate of Clinical Trials Is Higher than We Thought Instead of less than 10% of drugs reaching the market, a new study has found that almost 15% of new compounds pass clinical trials – which still suggests that it is pretty tough. Clinical trials give us a chance to test how a new drug or therapy interacts with the body and whether it is […] February 2, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2018 3D Printing with Living Cells Could Revolutionize Tissue Engineering Scientists at the University of Twente have managed to 3D print structures with living cells, which could boost the field of tissue engineering. Researchers at the University of Twente in the Netherlands have used a technique called ‘in-air microfluidics’ to 3D print structures that contain living cells. The work, which was published in Science Advances, allows […] February 1, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2018 New Diagnostic Tests On the Way as Qiagen Snaps Up a Spanish Biotech Qiagen will acquire Spanish biotech STAT-Dx for up to €153M – more than 3 times the total funding it has raised so far – to produce fast and effective diagnostic tests for infections and cancer. Molecular diagnostics company Qiagen has agreed to acquire STAT-Dx, a Spanish biotech that focuses on developing tools to provide fast […] February 1, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2018 New Biotech Launched to Fight Cognitive Impairment Caused by Alzheimer’s Syndesi Therapeutics has been formed by UCB and a group of investors, including Novo Seeds and V-Bio to develop a group of compounds for cognitive disorders caused by diseases like Alzheimer’s. Syndesi Therapeutics will use of Belgian biotech UCB’s expertise in drug discovery for neurological conditions to develop new therapies in cognitive disorders using a new […] February 1, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jan 2018 Your Pee Could Be Used to Build an Artificial Adrenal Gland Scientists have started generating artificial glands using cells derived from urine, which will allow the study of adrenal disorders that affect growth, development, and metabolism. Researchers at Queen Mary University of London have used cells in urine to begin generating an artificial adrenal gland that could be used to treat adrenal gland disorders. The study, published in Cell Reports, […] January 31, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jan 2018 Gene Synthesizing Biotech Gets $12M to Boost the Synbio Field Evonetix has closed a Series A fundraising round to support the development of its gene synthesis platform, an important tool in the emerging synbio field. Evonetix, based in Cambridge, UK, is developing a scalable, high fidelity gene synthesis approach that could be a key tool in the growing synbio field. The biotech has closed a […] January 31, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jan 2018 The Construction of an Industrial Algae Production Plant Begins in Austria BDI-BioEnergy produces algae for the food, pharma, and cosmetics industries. Now, it will build an industrial production plant to house its technology. BDI-BioEnergy is a specialized plant engineering company based in Styria, Austria. On Saturday, the company signaled the start of the construction of an industrial plant that will use its photobioreactor system to produce algae biomass. […] January 30, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email